Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$22,215 Mln
Revenue (TTM)
$11,035 Mln
Net Profit (TTM)
$992 Mln
ROE
0.1 %
ROCE
7.1 %
P/E Ratio
22.8
P/B Ratio
3.1
Industry P/E
--
EV/EBITDA
13
Div. Yield
1.6 %
Debt to Equity
1
Book Value
$64
EPS
$8.9
Face value
--
Shares outstanding
109,866,320
CFO
$13,663.00 Mln
EBITDA
$17,322.00 Mln
Net Profit
$9,502.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
| 12.0 | -4.9 | 10.4 | 12.7 | 13.9 | 9.4 | 10.7 |
|
BSE Sensex
| -12.4 | -11.4 | -12.2 | -1.5 | 8.6 | 8.6 | 11.5 |
|
S&P 100
| -7.0 | -4.5 | -5.4 | 18.5 | 21.6 | 12.6 | 13.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
| 15.0 | 9.3 | -11.9 | -9.6 | 47.9 | 14.1 | 31.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Quest Diagnostics (DGX)
|
194.4 | 22,215.1 | 11,035.0 | 992.0 | 13.2 | 14.2 | 22.8 | 3.1 |
| 72.5 | 96,853.4 | 4,02,067.0 | 1,768.0 | 1.3 | 2.3 | 54.8 | 1.3 | |
| 97.9 | 10,098.8 | 5,935.2 | 566.2 | 18.1 | 25.1 | 18.1 | 4.1 | |
| 71.0 | 2,278.1 | 427.5 | -21.0 | -4.4 | -7.6 | -- | 7.4 | |
| 498.0 | 1,19,183.9 | 75,600.0 | 6,784.0 | 16.0 | -159.1 | 18.8 | 293.4 | |
| 263.9 | 21,869.0 | 13,951.7 | 876.5 | 9.5 | 10.5 | 25.2 | 2.5 | |
| 201.6 | 26,624.2 | 2,306.1 | -208.2 | -11.2 | -14.3 | -- | 15.5 | |
| 203.1 | 20,005.3 | 21,310.0 | 1,407.0 | 16.9 | 33.5 | 14.7 | 4.6 | |
| 200.8 | 12,186.8 | 5,057.8 | 344.0 | 9.2 | 16.9 | 36 | 5.5 | |
| 187.1 | 11,754.3 | 17,364.8 | 1,488.8 | 12.2 | 21.4 | 8.3 | 1.6 |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing,... and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Read more
Chairman, CEO & President
Mr. James E. Davis
Executive VP & CFO
Mr. Sam A. Samad
Headquarters
Secaucus, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Quest Diagnostics Incorporated (DGX) is $194.39 (NYSE) as of 19-Mar-2026 14:42 EDT. Quest Diagnostics Incorporated (DGX) has given a return of 13.91% in the last 3 years.
The P/E ratio of Quest Diagnostics Incorporated (DGX) is 22.82 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.59
|
2.71
|
|
2024
|
19.57
|
2.52
|
|
2023
|
18.24
|
2.47
|
|
2022
|
19.02
|
3.05
|
|
2021
|
10.84
|
3.36
|
The 52-week high and low of Quest Diagnostics Incorporated (DGX) are Rs 213.50 and Rs 157.20 as of 20-Mar-2026.
Quest Diagnostics Incorporated (DGX) has a market capitalisation of $ 22,215 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Quest Diagnostics Incorporated (DGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.84
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.